FDA Approves Moderna Flu Shot
The FDA cleared Moderna's mRNA flu vaccine, the first of its kind.
August 7, 2026 · Updated Aug 7, 10:16am ET
30%
Left · 5
35%
Center · 6
35%
Right · 6
Pano rates the coverage Balanced.
What happened
The FDA approved Moderna’s mFlusiva, the first U.S. seasonal influenza vaccine made with mRNA technology, for adults ages 50 and older. The decision gives full approval for ages 50 to 64 and accelerated approval for adults 65 and older, with Moderna required to run an additional clinical trial in the older group. In a late-stage trial, mFlusiva was about 27% more effective than a standard flu shot, and Moderna expects it to be available for the 2026-2027 flu season.
Moderna Flu Vaccine Review
Part of the storyline · Storyline →- Aug 7FDA Approves Moderna Flu Shot (this story)Balanced
- Aug 6FDA Approves Moderna Flu ShotBalanced








